REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will ...

Discover Sanfilippo Syndrome a rare genetic disorder affecting childrens development Learn about its symptoms treatment ...

Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will feature oral and poster presentations at the upcoming ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") announced today that it will present at the 21st Annual WORLDSymposiumtm 2025, held February 3-7, 2025, in San Diego, Calif. The poster presentations ...

Jupiter Neurosciences, Inc.’s JUNS share price has dipped by 59.50%, which has investors questioning if this is right time to ...

Wedbush upped their FY2024 EPS estimates for Ultragenyx Pharmaceutical in a report released on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will ...

It should improve his chances.” The disorder that Irfan had tested positive for was Mucopolysaccharidosis Type II (MPS II), ...

Stock analysts at Leerink Partnrs lifted their FY2024 EPS estimates for Ultragenyx Pharmaceutical in a report released on ...

REGENXBIO Inc., a leading clinical-stage biotechnology company, and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced a strategic partnership for the development and commercialization of RGX-121 ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of ...